Show simple item record

dc.contributor.authorPainous, C.
dc.contributor.authorMartí, M.J.
dc.contributor.authorGraessner, H.
dc.contributor.authorCamargo, A.P.
dc.contributor.authorEl-Jaafary, S.I.
dc.contributor.authorMartínez-Ramírez, D.
dc.contributor.authorOjo, O.O.
dc.contributor.authorTaiwo, F.T.
dc.contributor.authorRajan, R.
dc.contributor.authorCornejo-Olivas, M.
dc.contributor.authorAyele, B.A.
dc.contributor.authorTibar, H.
dc.contributor.authorKearney, M.
dc.contributor.authorGatto, E.
dc.contributor.authorTijssen, M.A.
dc.date.accessioned2025-10-31T18:32:11Z
dc.date.available2025-10-31T18:32:11Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.12805/4511
dc.description.abstractTo evaluate the management of rare movement disorders (RMD) at the international level and identify care needs to be addressed, the Rare Movement Disorders Study Group of the International Parkinson and Movement Disorders Society (MDS) has conducted an exploratory survey. We sent an online survey to experts in Africa, Asia, Oceania and American continents following the classification of the MDS Regional Sections: Africa, Asia and Oceania (A&O), and Pan-America. We did not include Europe as the European Reference Network for Rare Neurological Diseases recently performed a similar care needs survey across European countries. We obtained responses from experts from 20 African, 26 A&O and 19 Pan-American countries. According to the respondents, only 55% of African countries had movement disorders experts, while these were present in 96% of A&O and 91% of Pan-American. Access to care for patients with RMD was stated difficult in 70% of African, 54% of A&O, and 65% of Pan-American countries. Africa was the region with greatest difficulties in accessing diagnostic tests. However, in Pan-America and A&O, large inequalities were observed between countries with quite variable access to therapeutic options such as deep brain stimulation. The survey results reflect wide variability in the management of RMD and provide evidence that a worldwide care-focused network is highly warranted. Scientific and medical organisations should raise awareness of deficits in managing RMD and care disparities among regions. The goals should be to facilitate the training of professionals, establish improvement strategies, and increase support and budgeting for these diseases.en_US
dc.description.sponsorshipThis work was not supported by any funding.
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofurn:issn:1873-5126
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSDG 3en_US
dc.subjectBioactive Peptides and Antioxidant Properties in Healthen_US
dc.subjectEnhancing Care Pathways for Rare Diseasesen_US
dc.titleManagement of rare movement diseases in different world regionsen_US
dc.typehttps://purl.org/coar/resource_type/D97F-VB57
dc.identifier.doihttps://doi.org/10.1016/j.parkreldis.2023.105286
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.25
dc.type.otherCommentary, Perspective u Opinion
dc.identifier.journalParkinsonism and Related Disorders
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2